APA (7th ed.) Citation

Abushakra, S., Doraiswamy, P. M., Hey, J. A., Tosun, D., Barkhof, F., Barakos, J., . . . McLaine, R. (2026). Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials. CNS Drugs, 40(2), 199. https://doi.org/10.1007/s40263-025-01251-y

Chicago Style (17th ed.) Citation

Abushakra, Susan, et al. "Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials." CNS Drugs 40, no. 2 (2026): 199. https://doi.org/10.1007/s40263-025-01251-y.

MLA (9th ed.) Citation

Abushakra, Susan, et al. "Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials." CNS Drugs, vol. 40, no. 2, 2026, p. 199, https://doi.org/10.1007/s40263-025-01251-y.